Abvc Biopharma (ABVC) Current Assets (2010 - 2026)

Abvc Biopharma (ABVC) has reported Current Assets for 16 consecutive years, with $411729.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Assets fell 85.14% year-over-year to $411729.0; the trailing twelve-month figure through Jun 2026 stood at $411729.0 (down 85.14% YoY), and the FY2025 full-year result was $2.5 million, up 14.75% from the prior year.
• Current Assets fell to $411729.0 in Q2 2026 per ABVC's latest filing, from $648848.0 in the prior quarter.
• Across five years, Current Assets topped out at $9.8 million in Q2 2022 and bottomed at $411729.0 in Q2 2026.
• Historically, Current Assets has averaged $2.9 million across 5 years, with a median of $2.4 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Current Assets soared 169.86% in 2022, then plunged 85.14% in 2026.
• Over 5 years, Current Assets stood at $3.0 million in 2022, then sank by 44.54% to $1.7 million in 2023, then jumped by 31.58% to $2.2 million in 2024, then rose by 14.75% to $2.5 million in 2025, then tumbled by 83.54% to $411729.0 in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $411729.0, $648848.0, and $2.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.